Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [2]. Core Views - The company has signed a five-year exclusive distribution agreement with 3B Medical, Inc. for the sale of sleep apnea treatment devices in the U.S. and Canada, which is expected to improve overseas order trends [4][7]. - The company reported a revenue of 602 million yuan for the first three quarters of 2024, a year-on-year decline of 36.31%, but showed signs of recovery with a 10.51% increase in revenue for the third quarter compared to the previous year [3][7]. - The report anticipates significant growth in U.S. orders due to the recovery of 3B Medical's order volume to industry norms and the introduction of new products [4][7]. Summary by Sections Company Overview - Latest closing price: 75.79 yuan - Total shares: 0.90 billion, circulating shares: 0.57 billion - Total market capitalization: 6.8 billion yuan, circulating market capitalization: 4.3 billion yuan - 52-week high/low: 126.50/56.99 yuan - Debt-to-asset ratio: 4.5% - Price-to-earnings ratio: 16.30 [1]. Financial Performance - For Q3 2024, the company achieved a net profit of 32.74 million yuan, a year-on-year increase of 21.78% [3]. - The company expects revenues of 926 million yuan, 1.243 billion yuan, and 1.442 billion yuan for 2024, 2025, and 2026 respectively, with corresponding growth rates of -17.5%, 34.2%, and 16.0% [7][8]. Market Strategy - The company has tailored its sales strategies for different regions, including establishing a consumables team in the U.S. and expanding its services in Europe through a new subsidiary [5]. - The report highlights the increasing public awareness of obstructive sleep apnea (OSA) health management, driven by advancements in wearable technology [5][6]. Earnings Forecast - The company is expected to see a turnaround in performance, with projected net profits of 230 million yuan, 307 million yuan, and 375 million yuan for 2024, 2025, and 2026, respectively [7][8].
怡和嘉业：美国去库接近尾声，看好公司海外订单改善趋势